Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2003 monograph topics are tositumomab, omalizumab, emtricitabine, testosterone buccal system mucoadhesive, and alfuzosin. The DUE is on omalizumab.
Get full access to this article
View all access options for this article.
References
1.
Factive [package literature]. Genesoft Pharmaceuticals; April 3, 2003.
2.
Food and Drug Administration.FDA Briefing Package: New Drug Application (NDA) 21–158 Factive (gemifloxacin). Anti-Infective Drugs Advisory Committee. March 4, 2003. www.fda.gov. Accessed March 3, 2003.
3.
Fernandez-RoblasR.In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens.J Antimicrob Chemother.2000; 46: 1023–7.
4.
BerronS.In vitro susceptibilities of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 other antimicrobial agents.Antimicrob Agents Chemother.2000; 44: 2543–4.
5.
GoldsteinE.J.C.In vitro activity of gemifloxacin (SB 265805) against anaerobes.Antimicrob Agents Chemother.1999; 43: 2231–5.
6.
GoldsteinE.J.C.In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.Diagn Micro Infect Dis.2002; 42: 113–8.
7.
KleinkaufN.Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.Antimicrob Agents Chemother.2001; 45: 1896–9.
8.
FileT.M.Jr.. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin.J Antimicrob Chemother.2001; 48: 67–74.
9.
RittenhouseS.In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.J Antimicrob Chemother.2000; 45(suppl S1):23–7.
10.
HobanD.J.A comparative in vitro surveillance study of gemifloxacin activities against 2632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America.Antimicrob Agents Chemother.2000; 44: 3008–11.
11.
Perez-TralleroE.Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.Antimicrob Agents Chemother.2002; 46: 2665–7.
12.
FuentesF.In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.Eur J Clin Microbiol Infect Dis.2000; 19: 137–9.
13.
PrietoJ.Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.Int J Antimicrob Agents.2001; 18: 231–8.
14.
Garcia-CalvoG.Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: Phase I study.Antimicrob Agents Chemother.2001; 45: 1876–8.
15.
NaberC.K.Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers.Antimicrob Agents Chemother.2001; 45: 3524–30.
16.
HobanD.J.Comparative in vitro activity of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.Eur J Clin Microbiol Infect Dis.2001; 20: 814–9.
17.
McCloskeyL.In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.J Antimicrob Chemother.2000; 45(suppl S1):13–21.
18.
DeshpandeL.M.Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).Diagn Micro Infect Dis.2000; 37: 139–42.
19.
KoethL.M.Comparative in vitro activity of gemifloxacin to other fluoroquinolones and nonquinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999–2000.Int J Antimicrob Agents.2002; 19: 33–7.
20.
HobanD.J.Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.Diagn Micro Infect Dis.2001; 40: 51–7.
21.
BoswellF.J.Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.J Antimicrob Chemother.2002; 50: 495–502.
22.
KingA.Comparative in vitro activity of gemifloxacin.J Antimicrob Chemother.2000; 45(suppl S1):1–12.
23.
DaviesT.A.Antipneumococcal activities of gemifloxacin compared to those of nine other agents.Antimicrob Agents Chemother.2000; 44: 304–10.
24.
GeeT.Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.J Antimicrob Chemother.2001; 47: 431–4.
25.
AllenA.Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.Antimicrob Agents Chemother.2001; 45: 540–5.
26.
AllenA.The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers.Int J Antimicrob Agents.2000; 16: 45–50.
27.
AllenA.Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.Antimicrob Agents Chemother.2000; 44: 1604–8.
28.
AllenA.Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers.Chemotherapy.1999; 45: 496–503.
29.
NaberK.G.Pharmacokinetics and penetration of gemifloxacin versus ofloxacin into prostate secretion and ejaculate after single oral dosing in volunteers [abstract]. 37th Infectious Disease Society America Annual Meeting; November 18–21, 1999; Philadelphia.
30.
DavyM.Pharmacokinetics and tolerability of gemifloxacin in healthy Japanese and Caucasian volunteers [abstract 2264]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
31.
PayV.Multiple-dose pharmacokinetics and tolerability of gemifloxacin following once-daily repeat oral 320 mg doses to healthy elderly volunteers [abstract 2265]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
32.
CottagnoudP.Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.Antimicrob Agents Chemother.2002; 46: 1607–9.
33.
DavyM.Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers.Chemotherapy.1999; 45: 478–84.
34.
LodeH.Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability.Clin Ther.2002; 11: 1915–36.
35.
BallP.Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.Int J Antimicrob Agents.2001; 18: 19–27.
36.
WilsonR.A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.Clin Ther.2002; 24: 639–52.
37.
HalpernM.T.Cost-effectiveness of gemifloxacin: Results from the GLOBE study.Am J Health Syst Pharm.2002; 59: 1357–65.
38.
BallP.Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: A randomized, double-blind comparison with trovafloxacin.J Chemother.2001; 13: 288–98.
39.
FileT.Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.J Chemother.2000; 12: 314–25.
40.
WilsonR.Oral gemifloxacin once daily for 5 days compared with sequential therapy with IV ceftriaxone/oral cefuroxime (maximum 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis.Respir Med.2003; 97: 242–9.
41.
FergusonB.J.Short treatment durations for acute bacterial rhinosinusitis: Five days of gemifloxacin versus 7 days of gemifloxacin.Otolaryngol Head Neck Surg.2002; 127: 1–6.
42.
FergusonB.J.Efficacy of once daily gemifloxacin for 7 days compared with cefuroxime axetil twice daily for 10 days in the treatment of acute bacterial sinusitis [abstract 814]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
43.
BirdN.Assessment of the effect of gemifloxacin on QTc interval in healthy volunteers [abstract 821]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
44.
GoldbergerM.J.FDA approval letter: NDA21–158. April 4, 2003. www.fda.org. Accessed April 18, 2003.
45.
HenkelT.J.Safety of gemifloxacin in patients aged > 65 years with respiratory and urinary tract infections [abstract 813]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
46.
VousdenM.Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin.Chemotherapy.1999; 45: 512–20.
47.
AllenA.Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers.Chemotherapy.1999; 45: 504–11.
48.
LodeH.Effect of calcium carbonate on the bioavailability of gemifloxacin in healthy volunteers [abstract 2266]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2000; Toronto.
49.
VousdenM.Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers.Chemotherapy.1999; 45: 485–90.
50.
DavyM.Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.Chemotherapy.1999; 45: 491–5.
51.
Anonymous [press release].Genesoft acquires North American and European rights to the novel quinolone antibiotic Factive from LG Life Sciences. GeneSoft. October 22, 2002.
